{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:43:53Z","timestamp":1787010233821,"version":"build-2736575974"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:p>Kawasaki disease (KD) is an acute systemic vasculitis of unknown etiology. KD can be complicated with macrophage activation syndrome. The optimal treatment for this KD complication has not been established, and a variety of treatments have been used. Infliximab, a chimeric monoclonal antibody that binds tumor necrosis factor, has proved to be efficacious in IV gammaglobulin resistant KD. We present 2 cases of KD complicated with macrophage activation syndrome, including 1 patient with DiGeorge syndrome successfully treated with a combined treatment of IV gammaglobulin, corticosteroids, cyclosporine, and infliximab.<\/jats:p>","DOI":"10.1097\/mph.0000000000001756","type":"journal-article","created":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T23:51:44Z","timestamp":1582242704000},"page":"e448-e451","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Use of Infliximab in the Treatment of Macrophage Activation Syndrome Complicating Kawasaki Disease"],"prefix":"10.1097","volume":"43","author":[{"given":"Leonardo","family":"Rivera-Rodriguez","sequence":"first","affiliation":[{"name":"Pediatric Cardiology Department, National Institute of Cardiology Ignacio Chavez, Mexico City"},{"name":"Pediatric Department, Medica Sur Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Pardo-D\u00edaz","sequence":"additional","affiliation":[{"name":"Clinical Immunology Department"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarbelio","family":"Moreno-Espinosa","sequence":"additional","affiliation":[{"name":"Pediatric Department, Medica Sur Hospital"},{"name":"Teaching Department, Federico Gomez, Children\u2019s Hospital, Mexico City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Scheffler-Mendoza","sequence":"additional","affiliation":[{"name":"Clinical Immunology Department"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A.","family":"Ruiz-Ontiveros","sequence":"additional","affiliation":[{"name":"Pediatric Department, Medica Sur Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Martin","family":"Garrido-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Cardiology Department, National Institute of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Iglesias-Amaya","sequence":"additional","affiliation":[{"name":"Clinical Immunology Department"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco A.","family":"Yamazaki-Nakashimada","sequence":"additional","affiliation":[{"name":"Pediatric Department, Medica Sur Hospital"},{"name":"Clinical Immunology Department"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,2,19]]},"reference":[{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/MPH.0000000000000872","article-title":"Kawasaki disease complicated with macrophage activation syndrome: a systematic review","volume":"39","author":"Garc\u00eda-Pav\u00f3n","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40272-019-00367-1","article-title":"Macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in childhood inflammatory disorders: diagnosis and management","volume":"22","author":"Henderson","year":"2020","journal-title":"Paediatr Drugs"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jpeds.2010.10.012","article-title":"Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study","volume":"158","author":"Son","year":"2011","journal-title":"J Pediatr"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1038\/s41598-017-18387-7","article-title":"Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial","volume":"8","author":"Mori","year":"2018","journal-title":"Sci Rep"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"115.e3","DOI":"10.1016\/j.jpeds.2017.10.013","article-title":"Infliximab for the treatment of refractory Kawasaki disease: a nationwide survey in Japan","volume":"195","author":"Masuda","year":"2018","journal-title":"J Pediatr"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/1756-185X.13208","article-title":"Adjunctive therapies in Kawasaki disease","volume":"21","author":"Tremoulet","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/MPH.0b013e3181dccbf4","article-title":"Macrophage activation syndrome in the acute phase of Kawasaki disease","volume":"32","author":"Latino","year":"2010","journal-title":"J Pediatr Hematol Oncol"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s00296-019-04382-w","article-title":"Kawasaki disease and immunodeficiencies in children: case reports and literature review","volume":"39","author":"Rivas-Larrauri","year":"2019","journal-title":"Rheumatol Int"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1002\/ajmg.a.38319","article-title":"The immune deficiency of chromosome 22q11.2 deletion syndrome","volume":"173","author":"Morsheimer","year":"2017","journal-title":"Am J Med Genet A"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1157\/13126553","article-title":"Revision de 22 casos de deleci\u00f3n 22q11.2: espectro fenot\u00edpico [Review of 22 cases with 22q11.2 deletion syndrome: phenotypic spectrum]","volume":"69","author":"Ballesta-Martinez","year":"2008","journal-title":"An Pediatr"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/ajmg.a.38474","article-title":"The 22q11.2 deletion syndrome: cancer predisposition, platelet abnormalities and cytopenias","volume":"176","author":"Lambert","year":"2018","journal-title":"Am J Med Genet A"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2014.121608","article-title":"The syndrome of hemophagocytic lymphohistiocytosis in primaryimmunodeficiencies: implications for differential diagnosis and pathogenesis","volume":"100","author":"Bode","year":"2015","journal-title":"Haematologica"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/(SICI)1096-8628(19991203)87:4<329::AID-AJMG9>3.0.CO;2-M","article-title":"Hemophagocytic lymphohistiocytosis in a patient with deletion of 22q11.2","volume":"87","author":"Aric\u00f2","year":"1999","journal-title":"Am J Med Genet"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajmg.a.10122","article-title":"Del 22Q11.2 and hemophagocytic lymphohistiocytosis: a non-random association","volume":"116A","author":"Cesaro","year":"2003","journal-title":"Am J Med Genet A"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/rheumatology\/keq218","article-title":"Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients","volume":"50","author":"Miettunen","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/rheumatology\/keg187","article-title":"Hemophagocytic syndrome in a rheumatoid arthritis patient treated with infliximab","volume":"42","author":"Aouba","year":"2003","journal-title":"Rheumatology"},{"key":"R19-20250804","first-page":"635","article-title":"Macrophage activation syndrome associated with etanercept in a child with systemic onset juvenile idiopathic arthritis","volume":"11","author":"N\u00e1dia","year":"2009","journal-title":"Isr Med Assoc J"},{"key":"R20-20250804","first-page":"401","article-title":"Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis","volume":"30","author":"Ramanan","year":"2003","journal-title":"J Rheumatol"},{"key":"R21-20250804","first-page":"e4548","article-title":"An elusive diagnosis: case reports of secondary hemophagocytic lymphohistiocytosis and review of current literature","volume":"11","author":"Tong","year":"2019","journal-title":"Cureus"},{"key":"R22-20250804","first-page":"241","article-title":"Macrophage activation syndrome after etanercept treatment","volume":"34","author":"Sandhu","year":"2007","journal-title":"J Rheumatol"},{"key":"R23-20250804","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00124743-200108000-00013","article-title":"Worsening of macrophage activation syndrome in a patient with adult onset Still\u2019s disease after initiation of etanercept therapy","volume":"7","author":"Stern","year":"2001","journal-title":"J Clin Rheumatol"},{"key":"R24-20250804","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1086\/500262","article-title":"Cytomegalovirus ileitis and hemophagocytic syndrome associated with use of anti-tumor necrosis factor-alpha antibody","volume":"42","author":"Kohara","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R25-20250804","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2169\/internalmedicine.51.5687","article-title":"Hemophagocytic lymphohistiocytosis in a rheumatoid arthritis patient treated with infliximab","volume":"51","author":"Oda","year":"2012","journal-title":"Intern Med"},{"key":"R26-20250804","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajh.20462","article-title":"Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis","volume":"81","author":"Henzan","year":"2006","journal-title":"Am J Hematol"},{"key":"R27-20250804","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/rheumatology\/kem205","article-title":"Successful treatment of refractory lupus-associated haemophagocytic lymphohistiocytosis with infliximab","volume":"46","author":"Ideguchi","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"R28-20250804","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.2169\/internalmedicine.7966-16","article-title":"Hemophagocytic syndrome complicated with dermatomyositis controlled successfully with infliximab and conventional therapies","volume":"56","author":"Komiya","year":"2017","journal-title":"Intern Med"},{"key":"R29-20250804","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3109\/s10165-011-0500-1","article-title":"Etanercept for the treatment of intractable hemophagocytic syndrome with systemic lupus erythematosus","volume":"22","author":"Kikuchi","year":"2012","journal-title":"Mod Rheumatol"},{"key":"R30-20250804","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3109\/s10165-007-0006-z","article-title":"Successful use of etanercept in the treatment of acute lupus hemophagocytic syndrome","volume":"18","author":"Takahashi","year":"2008","journal-title":"Mod Rheumatol"},{"key":"R31-20250804","first-page":"2120","article-title":"Etanercept in the treatment of macrophage activation syndrome","volume":"28","author":"Prahalad","year":"2001","journal-title":"J Rheumatol"},{"key":"R32-20250804","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/pbc.21019","article-title":"Etanercept for therapy-resistant macrophage activation syndrome","volume":"50","author":"Makay","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"R33-20250804","first-page":"414","article-title":"Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders","volume":"132","author":"Aeberli","year":"2002","journal-title":"Swiss Med Wkly"},{"key":"R34-20250804","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3109\/03009742.2010.508468","article-title":"Successful use of infliximab in macrophage activation syndrome with severe CNS involvement","volume":"40","author":"Sellmer","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"R35-20250804","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00296-011-2319-7","article-title":"Necrotizing fasciitis in a pediatric patient treated with etanercept and cyclosporine for macrophage activation syndrome","volume":"33","author":"Buonuomo","year":"2013","journal-title":"Rheumatol Int"},{"key":"R36-20250804","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","article-title":"An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder","volume":"104","author":"Jordan","year":"2004","journal-title":"Blood"},{"key":"R37-20250804","doi-asserted-by":"crossref","first-page":"1901.e3","DOI":"10.1053\/j.gastro.2017.02.004","article-title":"Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease","volume":"152","author":"Hyams","year":"2017","journal-title":"Gastroenterology"},{"key":"R38-20250804","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1546-0096-12-26","article-title":"High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report","volume":"12","author":"Shafferman","year":"2014","journal-title":"Pediatr Rheumatol Online J"},{"key":"R39-20250804","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.arcped.2012.04.016","article-title":"Intravenous immunoglobulin-resistant Kawasaki disease with hemophagocytosis","volume":"19","author":"Servel","year":"2012","journal-title":"Arch Pediatr"},{"key":"R40-20250804","doi-asserted-by":"crossref","first-page":"pii: e229708","DOI":"10.1136\/bcr-2019-229708","article-title":"High-dose anakinra as treatment for macrophage activation syndrome caused by refractory Kawasaki disease in an infant","volume":"12","author":"Lind-Holst","year":"2019","journal-title":"BMJ Case Rep"},{"key":"R41-20250804","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/INF.0b013e31817ecb6d","article-title":"Kawasaki disease associated with reactive hemophagocytic lymphohistiocytosis","volume":"27","author":"Cummings","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"R42-20250804","first-page":"e69170","article-title":"Prolonged fever and intravenous immunoglobulin resistance in Kawasaki diseaase: should macrophage activation syndrome be considered?","volume":"29","author":"Mousavi","year":"2019","journal-title":"Iran J Pediatr"},{"key":"R43-20250804","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/ng.3089","article-title":"An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome","volume":"46","author":"Canna","year":"2014","journal-title":"Nat Genet"},{"key":"R44-20250804","first-page":"1133","article-title":"Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis","volume":"34","author":"Behrens","year":"2007","journal-title":"J Rheumatol"},{"key":"R45-20250804","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.semarthrit.2016.08.007","article-title":"Should refractory Kawasaki disease be considered occult macrophage activation syndrome?","volume":"46","author":"Choi","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"R46-20250804","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.semarthrit.2014.07.007","article-title":"Macrophage activation syndrome in Kawasaki disease: more common than we thought?","volume":"44","author":"Wang","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"R47-20250804","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3109\/14397595.2015.1038430","article-title":"Utility of ferritin as a predictor of the patients with Kawasaki disease refractory to intravenous immunoglobulin therapy","volume":"25","author":"Yamamoto","year":"2015","journal-title":"Mod Rheumatol"},{"key":"R48-20250804","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cyto.2019.03.001","article-title":"Cytokine profile of macrophage activation syndrome associated with Kawasakidisease","volume":"119","author":"Jinkawa","year":"2019","journal-title":"Cytokine"},{"key":"R49-20250804","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/ped.13555","article-title":"Infliximab regulates monocytes and regulatory T cells in Kawasaki disease","volume":"60","author":"Koizumi","year":"2018","journal-title":"Pediatr Int"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001756","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:10:21Z","timestamp":1754338221000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,19]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001756","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,19]]},"assertion":[{"value":"2019-11-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}